Information about the Company

With a history tracing back to 2000, OrbusNeich Medical Group Holdings Limited (OrbusNeich) is a major global medical device manufacturer specializing in interventional instruments for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Backed by manufacturing bases in China and the Netherlands, as well as R&D centers in China and the U.S., the group has a sales network in over 70 countries and regions. Besides that, OrbusNeich is expanding into neurovascular intervention and structural heart disease areas.

OrbusNeich’s vision is to improve patients’ quality of life, globally, for those with vascular disease through its pioneering technologies; while its missions are to achieve its vision by designing and delivering innovative treatment solutions. The group is driven by its core values of Integrity, Passion, Innovation, and Performance.

Innovative Corporate Culture & Growth Initiatives

OrbusNeich prioritizes the well-being of its employees and believes that this will ultimately lead to the transmission of positive values to society. OrbusNeich provides a healthy and safe work environment with appropriate work gear, safety inspections, and third-party assessments. It also promotes equal opportunities and encourages staff to give back to society through charity events and donations – it donated approximately USD560,000 to support academic research related to cardiovascular diseases, scholarships, and charity events in 2022.

OrbusNeich invests in its employees by providing induction training, regular performance reviews, and mentoring for newly-joined employees. Technical training is also provided to manufacturing employees in the People’s Republic of China (PRC) and the Netherlands to keep them up-to-date with the latest medical standards, procedures, and technology. Administrative and management staff also receive regular training in management skills and business operations.

Achievements & Impact

OrbusNeich is a global company with offices spanning three continents and close to 1,000 employees. The company was listed on the Main Board of The Stock Exchange of Hong Kong in December 2022 and included as a constituent in the Hang Seng Composite Index and Stock Connect in March 2023. The group’s first annual results after listing showed a record high revenue of USD136.8 million, with sales in the PRC and the U.S. achieving year-on-year growth of 38.1% and 122.6%, respectively.

OrbusNeich pursues sustainable growth and as of 31 December 2022, it held over 180 granted patents worldwide, with over 40 approved products and around 40 products in development, including several first-of-its-kind products. It has also increased its aggregate annual production capacity to 1.4 million balloon products and 56,000 stent products leveraging its production bases in the PRC and the Netherlands.

The group spares no effort in facilitating exchanges between physicians in developed and developing countries. Its Physician Exchange Programmes brings skilled physicians to certain developing countries to enhance their PCI/PTA capabilities and experience. The patients also benefit from improved accessibility and care.